@TheMac Here's your challenge.
There are anecdotal stories of Benadryl working for C19. Quinine, HCQ and Ivermectin. All of those reduce acetylcholine and, therefore, muscarinic and nicotinic receptor activity of organs.
Do they keep C19 from binding to organs? Is that the key to preventing C19? Do they disable the ability of C19 to bind to ACE2 receptors?
I was going to be a biochemist. [They] have biochemists working on these diabolical plots. So we need to look at mechanisms in the body. Thanks.
https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00215/full
https://www.the-scientist.com/news-opinion/receptors-for-sars-cov-2-present-in-wide-variety-of-human-cells-67496
https://pubmed.ncbi.nlm.nih.gov/15141377/
Frontiers | Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation | Psychiatry
Muscarinic receptors have been found to regulate many diverse functions, ranging from motivation and feeding to spatial navigation, an important and widely studied type of cognitive behavior. Systemic administration of non-selective antagonists of muscarinic receptors, such as scopolamine or atropin..
https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00215/full
"Researchers have also looked at the antihistamine clemastine, a M1 muscarinic receptor agonist"
https://neurologyacademy.org/articles/debate-why-have-remyelination-therapies-failed-the-wrong-remyelination-biology-or-the-wrong-drugs-ms-cutting-edge-science
Debate: Why have remyelination therapies failed –… | Neurology Academy
Uniquely practical education, producing specialist clinical leaders and transforming local healthcare.
https://neurologyacademy.org/articles/debate-why-have-remyelination-therapies-failed-the-wrong-remyelination-biology-or-the-wrong-drugs-ms-cutting-edge-science
